Abstract
Secreted protein acidic and rich in cysteine (SPARC) is widely expressed in the vascular smooth muscle cells (VSMCs) of human intracranial aneurysms (IAs), but the effect and underlying mechanism of SPARC on VSMCs during the formation and progression of IAs needs to be probed. Human umbilical arterial smooth muscle cells (HUASMCs) were treated with a gradient concentrations of SPARC in vitro for different time. Cell counting kit-8 (CCK-8) assay, cell cycle, and cell apoptosis were used to investigate the effect of SPARC on HUASMCs. After exposure to 2 and 4μg/ml SPARC, cell viability were 89.3±2.00%, and 87.57±2.17% (P<0.05 vs. control), respectively. Induced by 2μg/ml SPARC, the proportion of cells in G0/G1 phase was 74.77±1.33% (P<0.05 vs. control), and the early and late apoptosis ratio were 7.38±1.25% and 4.86±0.81% (P<0.01 vs. control), respectively. After exposure to 2μg/ml SPARC for 2, 6, 12, 24, and 48h, Western blot analysis showed that the protein level of p21 was upregulated significantly at 2-12h (P<0.05 vs. control), while the expression of p53 remained stable within 48h. The expression of Bax protein increased markedly and peaked at 24 (P<0.01 vs. control), while Bcl2 protein decreased significantly at 48h (P<0.01 vs. control). Cleaved caspase3 was also upregulated dramatically and peaked at 24h (P<0.05 vs. control). The protein level of MMP2 increased significantly and peaked at 24h (P<0.01 vs. control), while TIMP2 remained stable and even reduced at 48h (P<0.05 vs. control). Taken together, SPARC could arrest HUASMCs in G0/G1 phase by overexpression of p21 and induce mitochondria-mediated apoptosis in vitro, which could result in the decreased cell viability. Besides, SPARC might also lead to the activation of MMP2 instead of MMP9. These results indicated SPARC could reduce the self-repair capability and increase injury of media layer and internal elastic lamina of intracranial artery, which would disrupt the normal homeostatic mechanism controlling vascular repair, thus promoting the formation and progression of IAs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.